With the factor XI inhibitor, clinicians may have more flexibility when managing anticoagulation in this common scenario.

The annual risk of recurrent ischemic stroke in patients with atrial fibrillation (AF) is about 3.75%, despite around 92% of patients being on oral anticoagulants (OAC). The risk of recurrent stroke ...

Based on these numbers, the researchers estimated that 5-year cumulative risks of recurrent events were 17.4% for ischemic ...

Community cardiology specialist Dr Peter Savill discusses five key challenges for GPs in the management of atrial ...

As we observed World Heart Rhythm Week (June 2–8, 2025), the theme “One Heart, Many Rhythms” underscored the importance of ...

Peter Zimetbaum, MD He wrote: “Atrial fibrillation is often asymptomatic ... is the unintended consequence of initiating lifelong anticoagulation treatment in patients who may not need it ...

I've been diagnosed with atrial fibrillation. I've read that it puts me at greater risk of stroke. Can you tell me more about ...

There is an apparent underuse of warfarin in elderly patients with AF, as there is inconsistency in opinion among clinicians about who should receive anticoagulation. The risks of warfarin are ...

Patients with AF and ACHD that receive NOAC, compared with VKA, for stroke prevention have lower risk of all-cause mortality.

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

In this randomized trial, left atrial appendage closure was associated with lower bleeding than oral anticoagulation in patients who underwent catheter-based atrial fibrillation ablation. 2. Left ...

Sounds dramatic, but when it comes to certain dietary supplements, even a slight overdose can send your ticker into chaos. We ...